Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 9 points (-0.1%) at 12,786 as of Tuesday, Nov. 20, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,471 issues advancing vs. 1,424 declining with 128 unchanged. The Health Services industry currently sits down 0.2% versus the S&P 500, which is up 0.0%. On the negative front, top decliners within the industry include Quest Diagnostics ( DGX), down 1.5%, DENTSPLY International ( XRAY), down 1.2%, Fresenius Medical Care Corporation ( FMS), down 0.9% and WellPoint ( WLP), down 0.7%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. ResMed ( RMD) is one of the companies pushing the Health Services industry lower today. As of noon trading, ResMed is down $0.64 (-1.6%) to $40.08 on average volume Thus far, 759,417 shares of ResMed exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $39.73-$40.36 after having opened the day at $40.34 as compared to the previous trading day's close of $40.72. ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $5.6 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 60.3% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate ResMed a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ResMed Ratings Report now.